Search

Your search keyword '"Lee, Sunyoung S."' showing total 145 results
Start Over Author "Lee, Sunyoung S."
145 results on '"Lee, Sunyoung S."'

7. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean-Nicolas, Lee, Sunyoung S, Yavuz, Betul Gok, Mohamed, Yehia I, Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching-Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C, Wolff, Robert A, Allison, James Patrick, and Sharma, Padmanee

Published
2022
Full Text
View/download PDF

9. Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume

Author

Chang, Enoch, primary, Wong, Franklin C L, additional, Chasen, Beth A, additional, Erwin, William D, additional, Das, Prajnan, additional, Holliday, Emma B, additional, Koong, Albert C, additional, Ludmir, Ethan B, additional, Minsky, Bruce D, additional, Noticewala, Sonal S, additional, Smith, Grace L, additional, Taniguchi, Cullen M, additional, Rodriguez, Maria J, additional, Beddar, Sam, additional, Martin-Paulpeter, Rachael M, additional, Niedzielski, Joshua S, additional, Sawakuchi, Gabriel O, additional, Schueler, Emil, additional, Perles, Luis A, additional, Xiao, Lianchun, additional, Szklaruk, Janio, additional, Park, Peter C, additional, Dasari, Arvind N, additional, Kaseb, Ahmed O, additional, Kee, Bryan K, additional, Lee, Sunyoung S, additional, Overman, Michael J, additional, Willis, Jason A, additional, Wolff, Robert A, additional, Tzeng, Ching-Wei D, additional, Vauthey, Jean-Nicolas, additional, and Koay, Eugene J, additional

Published
2024
Full Text
View/download PDF

10. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.

Author

Mohamed, Yehia I., Lee, Sunyoung S., Demir, Tarik, Chamseddine, Shadi, Hu, Zishuo Ian, Xiao, Lianchun, Elsayes, Khaled, Morris, Jeffrey S., Wolff, Robert A., Hiatia, Rikita, Qayyum, Aliya, Rashid, Asif, Duda, Dan G., Yao, James C., LaPelusa, Michael, Koay, Eugene J., Mahvash, Armeen, Al Azzam, Ahmed, Dumbrava, Ecaterina E., and Hassan, Manal

Subjects
*CIRCULATING tumor DNA, *CANCER prognosis, *PROGRESSION-free survival, *OVERALL survival, *HEPATOCELLULAR carcinoma
Abstract

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising non-invasive marker for detection, diagnosis, treatment selection, and prognosis of hepatocellular carcinoma (HCC). OBJECTIVE: This study aimed to examine the utility of ctDNA as a prognostic and predictive tool in HCC patients treated with nivolumab. METHODS: We analyzed pre-treatment ctDNA from 44 HCC patients using comprehensive genomic testing on a commercially available platform. We utilized log rank test and univariate Cox models to correlate overall survival (OS) and progression-free survival (PFS) with ctDNA expressions. RESULTS: Of 44 patients, 77.3% were men with median age of 67 years. All but 3 patients had at least one alteration identified, and TP53 was the most commonly altered gene (52.3%). Median OS was 17.5 months (95% CI: 12.7, NA). Mutations involving PIK3CA, BRCA1, and CCND1 amplification were associated with shorter OS (P 0.0001, 0.0001 and 0.01, respectively). Median PFS time was 4.01 months (95% CI: 3.06, 9.33). Mutations involving KIT and PIK3CA were associated with shorter PFS (P 0.0001 and 0.0004, respectively), while mutation involving CTNNB1 were associated with longer PFS (p = 0.04). CONCLUSIONS: ctDNA profiling may provide a benefit for prediction of survival and progression of HCC patients treated with nivolumab. Future studies are needed for confirmation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features.

Author

Cao, Hop S Tran, Witt, Russell G, Elsayes, Khaled M, Baiomy, Ali A, Xiao, Lianchun, Palmquist, Sarah, Lee, Sunyoung S, Mohamed, Yehia I, Mahvash, Armeen, Tzeng, Ching-Wei D, Chun, Yun Shin, Koay, Eugene Jon, Rashid, Asif, Hassan, Manal M, Yao, James C, Vauthey, Jean-Nicolas, and Kaseb, Ahmed O

Subjects
PREDICTION models, RESEARCH funding, SEVERITY of illness index, MULTIVARIATE analysis, DESCRIPTIVE statistics, EXPERIMENTAL design, LONGITUDINAL method, RESEARCH methodology, CONFIDENCE intervals, HEPATOCELLULAR carcinoma, PREDICTIVE validity, OVERALL survival, PROPORTIONAL hazards models
Abstract

Background Accurate prognostic stratification of hepatocellular carcinoma (HCC) is vital for clinical trial enrollment and treatment allocation. Multiple scoring systems have been created to predict patient survival, but no standardized scoring systems account for radiologic tumor features. We sought to create a generalizable scoring system for HCC which incorporates standardized radiologic tumor features and more accurately predicts overall survival (OS) than established systems. Methods Clinicopathologic parameters were collected from a prospectively collected cohort of patients with HCC treated at a single institution. Imaging studies were evaluated for tumor characteristics. Patients were randomly divided into a training set for identification of covariates that impacted OS and a validation set. Cox models were used to determine the association of various factors with OS and a scoring system was created. Results We identified 383 patients with HCC with imaging and survival outcomes, n  = 255 in the training set and 128 in the validation cohort. Factors associated with OS on multivariate analysis included: tumor margin appearance on CT or MRI (hazard ratio [HR] 1.37, 95% CI, 1.01-1.88) with infiltrative margins portending worse outcomes than encapsulated margins, massive tumor morphology (HR 1.64, 95% CI, 1.06-2.54); >2 lesions (HR 2.06, 95% CI, 1.46-2.88), Child-Turcotte-Pugh class C (HR 3.7, 95% CI, 2.23-6.16), and portal vein thrombus (HR 2.41, 95% CI, 1.71-3.39). A new scoring system was developed and more predictive of OS than other well-established systems. Conclusions Incorporation of standardized imaging characteristics to established clinical and lab predictors of outcome resulted in an improved predictive scoring system for patients with HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

Author

Hassan, Manal M., primary, Li, Donghui, additional, Han, Younghun, additional, Byun, Jinyoung, additional, Hatia, Rikita I., additional, Long, Erping, additional, Choi, Jiyeon, additional, Kelley, Robin Kate, additional, Cleary, Sean P., additional, Lok, Anna S., additional, Bracci, Paige, additional, Permuth, Jennifer B., additional, Bucur, Roxana, additional, Yuan, Jian-Min, additional, Singal, Amit G., additional, Jalal, Prasun K., additional, Ghobrial, R. Mark, additional, Santella, Regina M., additional, Kono, Yuko, additional, Shah, Dimpy P., additional, Nguyen, Mindie H., additional, Liu, Geoffrey, additional, Parikh, Neehar D., additional, Kim, Richard, additional, Wu, Hui-Chen, additional, El-Serag, Hashem, additional, Chang, Ping, additional, Li, Yanan, additional, Chun, Yun Shin, additional, Lee, Sunyoung S., additional, Gu, Jian, additional, Hawk, Ernest, additional, Sun, Ryan, additional, Huff, Chad, additional, Rashid, Asif, additional, Amin, Hesham M., additional, Beretta, Laura, additional, Wolff, Robert A., additional, Antwi, Samuel O., additional, Patt, Yehuda, additional, Hwang, Lu-Yu, additional, Klein, Alison P., additional, Zhang, Karen, additional, Schmidt, Mikayla A., additional, White, Donna L., additional, Goss, John A., additional, Khaderi, Saira A., additional, Marrero, Jorge A., additional, Cigarroa, Francisco G., additional, Shah, Pankil K., additional, Kaseb, Ahmed O., additional, Roberts, Lewis R., additional, and Amos, Christopher I., additional

Published
2024
Full Text
View/download PDF

13. Characterizing outcomes of ERBB2-amplified biliary tract cancer.

Author

Fox, Daniel Aaron, primary, Haro-Silerio, Jaime, additional, Bhamidipati, Deepak, additional, Meric-Bernstam, Funda, additional, Pant, Shubham, additional, Ross, Jeffrey S., additional, Hu, Zishuo Ian, additional, Koay, Eugene Jon, additional, Ludmir, Ethan B., additional, Tran Cao, Hop Sanderson, additional, Tzeng, Ching-Wei D., additional, Chun, Yun Shin, additional, Vauthey, Jean-Nicolas, additional, Newhook, Timothy E., additional, Metwalli, Zeyad, additional, Habibollahi, Peiman, additional, Cox, Veronica L., additional, Kang, Hyunseon, additional, Javle, Milind M., additional, and Lee, Sunyoung S., additional

Published
2024
Full Text
View/download PDF

14. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.

Author

Dayyani, Farshid, primary, Baretti, Marina, additional, Lee, Sunyoung S., additional, He, Aiwu Ruth, additional, Kim, Richard D., additional, Lin, Bruce Shih-Li, additional, Enzler, Thomas, additional, Al Hallak, Mohammed Najeeb, additional, Ulahannan, Susanna Varkey, additional, Davis, S. Lindsey, additional, Burgoyne, Adam, additional, Tweardy, David, additional, Harding, James J., additional, Kaseb, Ahmed Omar, additional, de Achaval, Sofia, additional, Alibhai, Imran, additional, and Kauh, John S., additional

Published
2024
Full Text
View/download PDF

15. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA).

Author

Haro-Silerio, Jaime, primary, Fox, Daniel Aaron, additional, Bhamidipati, Deepak, additional, Hu, Zishuo Ian, additional, Koay, Eugene Jon, additional, Ludmir, Ethan B., additional, Tran Cao, Hop Sanderson, additional, Vauthey, Jean-Nicolas, additional, Newhook, Timothy E., additional, Tzeng, Ching-Wei D., additional, Chun, Yun Shin, additional, Mahvash, Armeen, additional, Metwalli, Zeyad, additional, Habibollahi, Peiman, additional, Cox, Veronica L., additional, Kang, Hyunseon, additional, Chatterjee, Deyali, additional, Kaseb, Ahmed Omar, additional, Javle, Milind M., additional, and Lee, Sunyoung S., additional

Published
2024
Full Text
View/download PDF

16. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.

Author

LaPelusa, Michael Brian, primary, Chamseddine, Shadi, additional, Xiao, Lianchun, additional, Hasanov, Elshad, additional, Bhosale, Priya, additional, Abugabal, Yehia I., additional, Gok Yavuz, Betul, additional, Yadav, Shalini S., additional, Tran Cao, Hop Sanderson, additional, Xu, Li, additional, Hu, Zishuo Ian, additional, Lee, Sunyoung S., additional, Sakamuri, Divya, additional, Curran, Michael A., additional, Jindal, Sonali, additional, Duda, Gabriel Dan, additional, Sharma, Padmanee, additional, Qayyum, Aliya, additional, and Kaseb, Ahmed Omar, additional

Published
2024
Full Text
View/download PDF

18. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.

Author

Chamseddine, Shadi, LaPelusa, Michael, Lianchun Xiao, Mohamed, Yehia I., Lee, Sunyoung S., Zishuo Ian Hu, Hatia, Rikita I., Hassan, Manal, Yao, James C., Duda, Dan G., Datar, Saumil, Amin, Hesham M., and Kaseb, Ahmed O.

Subjects
SOMATOTROPIN, HEPATOCELLULAR carcinoma, BIOMARKERS, CLINICAL trials, OVERALL survival
Abstract

Introduction: In this study, we explored the potential of plasma growth hormone (GH) as a prognostic biomarker in patients with advanced HCC treated with durvalumab plus tremelimumab (D+T). Methods: In this study, we included 16 patients with advanced HCC who received D+T at MD Anderson Cancer Center between 2022 and 2023 and had plasma GH measurements recorded before treatment. Plasma GH levels were measured from prospectively collected blood samples and were correlated with progression-free survival (PFS) and overall survival (OS). The cutoff for normal GH levels in women and men was defined as =3.7 µg/L and =0.9 µg/L, respectively. The Kaplan-Meier method was employed to compute the median OS and PFS, while the Log rank test was applied to compare the survival outcomes between the GH-high and GH-low groups. Results: Sixteen patients were included in this analysis, two female and fourteen male, with a median age of 65.5 years. At the time of the analysis, the 6-month OS rate was 100% among GH-low patients (6 patients) and 30% among GH-high patients (10 patients). OS was significantly longer in GH-low patients (not evaluable) compared to GH-high patients (3.94 months) (p = 0.030). PFS was also significantly longer in GH-low patients (not evaluable) compared to the GH-high patients (1.87 months) (p = 0.036). Conclusion: Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

Author

DiPeri, Timothy P., primary, Zhao, Ming, additional, Evans, Kurt W., additional, Varadarajan, Kaushik, additional, Moss, Tyler, additional, Scott, Stephen, additional, Kahle, Michael P., additional, Byrnes, Charnel C., additional, Chen, Huiqin, additional, Lee, Sunyoung S., additional, Halim, Abdel-Baset, additional, Hirai, Hiroshi, additional, Wacheck, Volker, additional, Kwong, Lawrence N., additional, Rodon, Jordi, additional, Javle, Milind, additional, and Meric-Bernstam, Funda, additional

Published
2023
Full Text
View/download PDF

20. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Author

Gok Yavuz, Betul, primary, Datar, Saumil, additional, Chamseddine, Shadi, additional, Mohamed, Yehia I., additional, LaPelusa, Michael, additional, Lee, Sunyoung S., additional, Hu, Zishuo Ian, additional, Koay, Eugene J., additional, Tran Cao, Hop S., additional, Jalal, Prasun Kumar, additional, Daniel-MacDougall, Carrie, additional, Hassan, Manal, additional, Duda, Dan G., additional, Amin, Hesham M., additional, and Kaseb, Ahmed O., additional

Published
2023
Full Text
View/download PDF

24. List of Contributors

Author

Abraham, Jame, primary, Advani, Anjali, additional, Basse, Per, additional, Bhatia, Shailender, additional, Boland, Patrick M., additional, Chen, Hongbin, additional, Dy, Grace K., additional, Ernstoff, Marc S., additional, Fountzilas, Christos, additional, Friedman, Gregory K., additional, Gillespie, G. Yancey, additional, Hanif, Ahmad, additional, Harrison, Michael R., additional, Inman, Brant A., additional, Ito, Fumito, additional, Iyer, Renuka V., additional, Kalinski, Pawel, additional, Khan, Sumera, additional, Kruse, Megan, additional, Lee, Sunyoung S., additional, Lee, Sylvia, additional, Loecher, Matthew, additional, Maawy, Ali A., additional, Mayor, Paul, additional, McNamara, Megan A., additional, Puzanov, Igor, additional, Ring, Eric K., additional, Sawalha, Yazeed, additional, Starbuck, Kristen, additional, Zhang, Tian, additional, and Zsiros, Emese, additional

Published
2019
Full Text
View/download PDF

25. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience

Author

Nardo, Mirella, primary, Yilmaz, Bulent, additional, Nelson, Blessie Elizabeth, additional, Torres, Harrys A, additional, Wang, Lan Sun, additional, Granwehr, Bruno Palma, additional, Song, Juhee, additional, Dalla Pria, Hanna R F, additional, Trinh, Van A, additional, Glitza Oliva, Isabella C, additional, Patel, Sapna P, additional, Tannir, Nizar M, additional, Kaseb, Ahmed Omar, additional, Altan, Mehmet, additional, Lee, Sunyoung S, additional, Miller, Ethan, additional, Zhang, Hao, additional, Stephen, Bettzy A, additional, and Naing, Aung, additional

Published
2023
Full Text
View/download PDF

26. Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases

Author

De, Brian, primary, Upadhyay, Rituraj, additional, Liao, Kaiping, additional, Kumala, Tiffany, additional, Shi, Christopher, additional, Dodoo, Grace, additional, Abi Jaoude, Joseph, additional, Corrigan, Kelsey L., additional, Manzar, Gohar S., additional, Marqueen, Kathryn E., additional, Bernard, Vincent, additional, Lee, Sunyoung S, additional, Raghav, Kanwal P.S., additional, Vauthey, Jean-Nicolas, additional, Tzeng, Ching-Wei, additional, Tran Cao, Hop S., additional, Lee, Grace, additional, Wo, Jennifer, additional, Hong, Theodore S, additional, Crane, Christopher H, additional, Minsky, Bruce D., additional, Smith, Grace L., additional, Holliday, Emma B., additional, Taniguchi, Cullen M., additional, Koong, Albert C., additional, Das, Prajnan, additional, Javle, Milind, additional, Ludmir, Ethan B., additional, and Koay, Eugene, additional

Published
2023
Full Text
View/download PDF

27. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.

Author

Chamseddine, Shadi, Mohamed, Yehia I., Lee, Sunyoung S., Yao, James C., Hu, Zishuo Ian, Tran Cao, Hop S., Xiao, Lianchun, Sun, Ryan, Morris, Jeffrey S., Hatia, Rikita I., Hassan, Manal, Duda, Dan G., Diab, Maria, Mohamed, Amr, Nassar, Ahmed, Datar, Saumil, Amin, Hesham M., and Kaseb, Ahmed Omar

Subjects
CYTOKINES, INTERLEUKINS, ACADEMIC medical centers, CONFIDENCE intervals, LOG-rank test, CARCINOGENESIS, HOSPITAL wards, DESCRIPTIVE statistics, TUMOR markers, HEPATOCELLULAR carcinoma, OVERALL survival, ONCOLOGY
Abstract

Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Dose-escalated pancreas radiotherapy for unresected pancreatic adenocarcinoma: Patterns of care and survival in the United States.

Author

Shi, Christopher, primary, De, Brian, additional, Florez, Marcus A., additional, Tran Cao, Hop Sanderson, additional, Lee, Sunyoung S., additional, Willis, Jason, additional, Noticewala, Sonal S, additional, Minsky, Bruce D., additional, Smith, Grace L., additional, Holliday, Emma, additional, Taniguchi, Cullen M., additional, Koong, Albert C., additional, Das, Prajnan, additional, Ludmir, Ethan B., additional, and Koay, Eugene Jon, additional

Published
2023
Full Text
View/download PDF

29. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis

Author

Dodoo, Grace N, primary, De, Brian, additional, Lee, Sunyoung S, additional, Abi Jaoude, Joseph, additional, Vauthey, Jean-Nicolas, additional, Tzeng, Ching-Wei D, additional, Tran Cao, Hop S, additional, Katlowitz, Kalman A, additional, Mandel, Jacob J, additional, Beckham, Thomas H, additional, Minsky, Bruce D, additional, Smith, Grace L, additional, Holliday, Emma B, additional, Koong, Albert C, additional, Das, Prajnan, additional, Taniguchi, Cullen M, additional, Javle, Milind, additional, Koay, Eugene J, additional, and Ludmir, Ethan B, additional

Published
2023
Full Text
View/download PDF

30. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Author

Mohamed, Yehia I., primary, Duda, Dan G., additional, Awiwi, Muhammad O., additional, Lee, Sunyoung S., additional, Altameemi, Lina, additional, Xiao, Lianchun, additional, Morris, Jeffrey S., additional, Wolff, Robert A., additional, Elsayes, Khaled M., additional, Hatia, Rikita I., additional, Qayyum, Aliya, additional, Chamseddine, Shadi M., additional, Rashid, Asif, additional, Yao, James C., additional, Mahvash, Armeen, additional, Hassan, Manal M., additional, Amin, Hesham M., additional, and Kaseb, Ahmed Omar, additional

Published
2022
Full Text
View/download PDF

33. Abstract 2618: Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in cholangiocarcinoma with FGFR fusions/rearrangements

Author

DiPeri, TImothy P., primary, Zhao, Ming, additional, Moss, Tyler, additional, Kahle, Michael, additional, Rauli, Payal, additional, Lee, Sunyoung S., additional, Halim, Abdel, additional, Hirai, Hiroshi, additional, Wacheck, Volker, additional, Benhadji, Karim, additional, Rodon, Jordi, additional, Javle, Milind, additional, and Meric-Bernstam, Funda, additional

Published
2022
Full Text
View/download PDF

34. Preservation of liver function with local radiation therapy in patients with metastatic intrahepatic cholangiocarcinoma with extrahepatic disease.

Author

Upadhyay, Rituraj, primary, Ludmir, Ethan B., additional, De, Brian, additional, Holliday, Emma, additional, Smith, Grace L., additional, Taniguchi, Cullen M., additional, Das, Prajnan, additional, Minsky, Bruce D., additional, Koong, Albert C., additional, Javle, Milind M., additional, Lee, Sunyoung S., additional, Vauthey, Jean-Nicolas, additional, Tzeng, Ching-Wei D., additional, Tran Cao, Hop, additional, and Koay, Eugene Jon, additional

Published
2022
Full Text
View/download PDF

36. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, Sharma, Padmanee, Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, and Sharma, Padmanee

Abstract

Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma. Methods: In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed. Findings: Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3–4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 pa

Published
2022

37. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States

Author

De, Brian, primary, Tran Cao, Hop S., additional, Vauthey, Jean‐Nicolas, additional, Manzar, Gohar S., additional, Corrigan, Kelsey L., additional, Raghav, Kanwal P. S., additional, Lee, Sunyoung S., additional, Tzeng, Ching‐Wei D., additional, Minsky, Bruce D., additional, Smith, Grace L., additional, Holliday, Emma B., additional, Taniguchi, Cullen M., additional, Koong, Albert C., additional, Das, Prajnan, additional, Javle, Milind, additional, Ludmir, Ethan B., additional, and Koay, Eugene J., additional

Published
2022
Full Text
View/download PDF

38. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Author

Manzar, Gohar Shahwar, primary, De, Brian Sandeep, additional, Abana, Chike Osita, additional, Lee, Sunyoung S., additional, Javle, Milind, additional, Kaseb, Ahmed O., additional, Vauthey, Jean-Nicolas, additional, Tran Cao, Hop Sanderson, additional, Koong, Albert C., additional, Smith, Grace Li, additional, Taniguchi, Cullen M., additional, Holliday, Emma Brey, additional, Das, Prajnan, additional, Koay, Eugene Jon, additional, and Ludmir, Ethan Bernard, additional

Published
2022
Full Text
View/download PDF

42. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma

Author

Gok Yavuz,Betul, Hasanov,Elshad, Lee,Sunyoung S, Mohamed,Yehia I, Curran,Michael A, Koay,Eugene J, Cristini,Vittorio, and Kaseb,Ahmed O

Subjects
Journal of Hepatocellular Carcinoma
Abstract

Betul Gok Yavuz,1 Elshad Hasanov,2 Sunyoung S Lee,1 Yehia I Mohamed,1 Michael A Curran,3 Eugene J Koay,4 Vittorio Cristini,5,6 Ahmed O Kaseb1 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX, USA; 6Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Ahmed O Kaseb Email akaseb@mdanderson.orgAbstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of care therapy in HCC. However, the current role of immunotherapy in HCC remains non-curative. Given this context, a high priority for oncology is understanding the biomarkers that predict clinical response to immunotherapy, have the potential to improve patient selection to maximize the clinical benefit, and spare unnecessary toxicity. In this review, we summarize the key predictive and prognostic biomarkers investigated in immunotherapy clinical trials in HCC and the emerging biomarkers to serve as a roadmap for future clinical trials. Biomarkers from tumoral tissues including PDL-1 expression, tissue infiltrating lymphocytes, tumor mutational burden (TMB) and specific immune signatures, and from peripheral blood including neutrophil-to-lymphocytes ratio, platelet-to-lymphocytes ratio, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific cytokines, along with gut microbiota are among the studied biomarkers to date in the HCC era. More integrative approaches, including mathematical biomarkers to predict immunotherapy outcomes, are yet to be studied in HCC.Keywords: hepatocellular carcinoma, immunotherapy, biomarker

Published
2021

43. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

Author

Kaseb, Ahmed Omar, primary, Kappadath, S Cheenu, additional, Lee, Sunyoung S, additional, Raghav, Kanwal Pratap, additional, Mohamed, Yehia I, additional, Xiao, Lianchun, additional, Morris, Jeffrey S, additional, Ohaji, Chimela, additional, Avritscher, Rony, additional, Odisio, Bruno C, additional, Kuban, Joshua, additional, Abdelsalam, Mohamed E, additional, Chasen, Beth, additional, Elsayes, Khaled M, additional, Elbanan, Mohamed, additional, Wolff, Robert A, additional, Yao, James C, additional, and Mahvash, Armeen, additional

Published
2021
Full Text
View/download PDF

44. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network

Author

Augustyn, Alexander, Reed, Valerie I., Ahmad, Neelofur, Bhutani, Manoop S., Bloom, Elizabeth S., Bowers, John R., Chronowski, Gregory M., Das, Prajnan, Holliday, Emma B., Delclos, Marc E., Huey, Ryan W., Koay, Eugene J., Lee, Sunyoung S., Nelson, Christopher L., Taniguchi, Cullen M., Koong, Albert C., and Chun, Stephen G.

Published
2021
Full Text
View/download PDF

45. Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test

Author

Mahalingam, Devalingam, primary, Chelis, Leonidas, additional, Nizamuddin, Imran, additional, Lee, Sunyoung S., additional, Kakolyris, Stylianos, additional, Halff, Glenn, additional, Washburn, Ken, additional, Attwood, Kristopher, additional, Fahad, Ibnshamsah, additional, Grigorieva, Julia, additional, Asmellash, Senait, additional, Meyer, Krista, additional, Oliveira, Carlos, additional, Roder, Heinrich, additional, Roder, Joanna, additional, and Iyer, Renuka, additional

Published
2021
Full Text
View/download PDF

49. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases

Author

De, Brian, Upadhyay, Rituraj, Liao, Kaiping, Kumala, Tiffany, Shi, Christopher, Dodoo, Grace, Abi Jaoude, Joseph, Corrigan, Kelsey L., Manzar, Gohar S., Marqueen, Kathryn E., Bernard, Vincent, Lee, Sunyoung S, Raghav, Kanwal P.S., Vauthey, Jean-Nicolas, Tzeng, Ching-Wei, Tran Cao, Hop S., Lee, Grace, Wo, Jennifer, Hong, Theodore S, Crane, Christopher H, Minsky, Bruce D., Smith, Grace L., Holliday, Emma B., Taniguchi, Cullen M., Koong, Albert C., Das, Prajnan, Javle, Milind, Ludmir, Ethan B., and Koay, Eugene

Abstract

Introduction:Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. Methods:We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5–97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling. Results:We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8–11) and 21 months (CI: 17–26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; p= 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; p= 0.005) and receipt of L-RT (HR: 0.40; p= 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; p< 0.001). Conclusion:For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results